Thermo Fisher wins contracts as pharma shifts production to US, CEO says
I'm PortAI, I can summarize articles.
Thermo Fisher Scientific has secured contracts to assist pharmaceutical companies in relocating production from Europe and Asia to the U.S., according to CEO Marc Casper. This trend, driven by a focus on reshoring, is expected to gain momentum in 2027 and 2028. Casper noted that the acquisition of Sanofi's manufacturing site in New Jersey was part of this expansion strategy. He also highlighted improving biotech funding and confidence in the pharmaceutical sector's collaboration with the U.S. administration, indicating a positive outlook for the industry.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments